FNY Investment Advisers LLC Buys 928 Shares of Eli Lilly and Company $LLY

FNY Investment Advisers LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 441.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,138 shares of the company’s stock after purchasing an additional 928 shares during the period. FNY Investment Advisers LLC’s holdings in Eli Lilly and Company were worth $887,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Chokshi & Queen Wealth Advisors Inc raised its stake in Eli Lilly and Company by 9.5% during the 2nd quarter. Chokshi & Queen Wealth Advisors Inc now owns 1,036 shares of the company’s stock worth $807,000 after buying an additional 90 shares during the period. D.A. Davidson & CO. raised its stake in Eli Lilly and Company by 5.0% during the 2nd quarter. D.A. Davidson & CO. now owns 46,111 shares of the company’s stock worth $35,945,000 after buying an additional 2,211 shares during the period. Blume Capital Management Inc. raised its stake in Eli Lilly and Company by 46.7% during the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares during the period. Gables Capital Management Inc. raised its stake in Eli Lilly and Company by 10.6% during the 2nd quarter. Gables Capital Management Inc. now owns 2,899 shares of the company’s stock worth $2,260,000 after buying an additional 278 shares during the period. Finally, Cullen Frost Bankers Inc. raised its stake in Eli Lilly and Company by 1.0% during the 2nd quarter. Cullen Frost Bankers Inc. now owns 103,839 shares of the company’s stock worth $80,946,000 after buying an additional 1,075 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. UBS Group dropped their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. The Goldman Sachs Group raised their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research note on Friday, October 10th. Guggenheim reissued a “buy” rating and issued a $948.00 price target on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Finally, Morgan Stanley dropped their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research note on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $938.61.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $799.85 on Wednesday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock’s 50-day simple moving average is $759.77 and its 200 day simple moving average is $766.43. The company has a market cap of $757.03 billion, a P/E ratio of 52.28, a P/E/G ratio of 1.16 and a beta of 0.47. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Activity

In other Eli Lilly and Company news, Director Jamere Jackson purchased 200 shares of the stock in a transaction on Friday, August 8th. The shares were purchased at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Daniel Skovronsky purchased 1,000 shares of the stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.